Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

VioGen Biosciences patents new PIKfyve inhibitors

Dec. 18, 2020

HSF1 inhibition directly targets treatment-resistant prostate cancer

Dec. 18, 2020

Chordia Therapeutics reports preclinical data for MALT1 inhibitor

Dec. 18, 2020

Pfizer conducts phase I study of PF-07248144 in advanced or metastatic solid tumors

Dec. 18, 2020

Interim phase II data for darolutamide demonstrate efficacy in advanced AR-positive TNBC

Dec. 17, 2020

Positive final data presented from COMBAT/KEYNOTE-202 triple combination study in PDAC

Dec. 17, 2020

Sichuan Haisco Pharmaceutical patents CRBN-comprising PROTACs

Dec. 17, 2020

Clinical benefit seen with SOR-007 in patients with cutaneous metastases

Dec. 16, 2020

PRDM2, a novel SMAD3-dependent immunosuppressor for promoting NSCLC

Dec. 16, 2020

SMAD3 as new therapeutic target for NSCLC

Dec. 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...